Ensign Peak Advisors’s Alpine Immune Sciences Inc ALPN Stock Holding History

Ensign Peak Advisors’s Portfolio ALPN Stock Details ALPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-140,043	Closed	-$5.55M	–	1753
2024 Q1	$5.55M	Buy	140,043 +10,068	+8%	+$297K	0.01%	609
2023 Q4	$2.48M	Buy	+129,975	New	+$1.81M	﹤0.01%	828
2022 Q2	–	Sell	-110,017	Closed	-$987K	–	2218
2022 Q1	$987K	Buy	110,017 +37,087	+51%	+$321K	﹤0.01%	1214
2021 Q4	$1.01M	Hold	72,930	–	–	﹤0.01%	1276
2021 Q3	$778K	Buy	72,930 +18,350	+34%	+$169K	﹤0.01%	1516
2021 Q2	$491K	Hold	54,580	–	–	﹤0.01%	1599
2021 Q1	$579K	Buy	54,580 +18,505	+51%	+$231K	﹤0.01%	1580
2020 Q4	$455K	Buy	+36,075	New	+$354K	﹤0.01%	1618

Ensign Peak Advisors's ALPN Position: Q2 2024 in Review

Ensign Peak Advisors sold out of Alpine Immune Sciences Inc (ALPN) in Q2 2024, closing a stake of 140,043 shares — an estimated $5.55M sold.

Ensign Peak Advisors first reported a position in ALPN in Q4 2020 and held it in 8 quarters. The position peaked at $5.55M in Q1 2024. 0 funds tracked by Wall St. Rank hold ALPN as of Q2 2024.

Ensign Peak Advisors reported no remaining Alpine Immune Sciences Inc position as of Q2 2024 after selling out during the quarter.
Ensign Peak Advisors sold 140,043 Alpine Immune Sciences Inc shares in Q2 2024, an estimated $5.55M.
Ensign Peak Advisors first reported a position in Alpine Immune Sciences Inc in Q4 2020 and held it in 8 quarters.
Ensign Peak Advisors's Alpine Immune Sciences Inc position peaked at $5.55M in Q1 2024.
0 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q2 2024.

Based on Ensign Peak Advisors's 13F filing for Q2 2024, filed 13 Aug 2024.